Genome Editing: Fetal Origins of AML in Down Syndrome, With Drs. Adam Mead & Elvin Wagenblast

Contributing Editor Dr. Adam Mead has a conversation with Dr. Elvin Wagenblast about a study that used CRISPR/Cas9 genome editing of hematopoietic stem and progenitor cells from human fetal liver to induce transient abnormal myelopoiesis– and myeloid leukemia associated with Down syndrome–related mutations.